All In Biotech

Drug Trial Radar · NCT05591755

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis

Evaluation of the Combination Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to Its Components and Vehicle in an Allergen BioCube® in Subjects With Seasonal Allergic Conjunctivitis

Last checked: Nov 19, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 229 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

229

Actual

Start

Nov 18, 2022

Primary completion

Aug 9, 2023

Study completion Aug 9, 2023

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Oct 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of Combo compared to its individual components and compared to vehicle in a population of subjects with seasonal allergic conjunctivitis.

Conditions

  • Seasonal Allergic Conjunctivitis

Interventions

  • Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic SolutionDrug

    Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution

  • Ketotifen fumarate ophthalmic solution 0.035%Drug

    Ketotifen fumarate ophthalmic solution 0.035%

  • Brimonidine tartrate ophthalmic solution 0.025%Drug

    Brimonidine tartrate ophthalmic solution 0.025%

  • Experimental: Vehicle ophthalmic solutionDrug

    Experimental: Vehicle ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular Itching Symptom ScoreTime frame: Assessed up to 480 minutes post-instillation of assigned IP
  2. Ocular Redness Measured by Ocular Itching ScaleTime frame: Assessed up to 480 minutes post-instillation of assigned IP

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • 104 Butchertown Clinical Trials

    Louisville, Kentucky

  • 101 Andover Eye Associates

    Andover, Massachusetts

  • 105 - Advancing Vision Research

    Goodlettsville, Tennessee

  • 102 Total Eye Care, PA

    Memphis, Tennessee

  • 108 Emerson Clinical Research Institute Inc.

    Falls Church, Virginia

  • 107 Virginia Eye Institute

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.